Consensus Report Urges Increased Support for the Metastatic Breast Cancer Community

Publication
Article
OncologyONCOLOGY Vol 22 No 11
Volume 22
Issue 11

The Metastatic Breast Cancer Advocacy Working Group, a cooperative of patient advocates from seven countries, released a consensus report urging other advocacy groups, health-care corporations and professionals, government, academia, community/religious organizations, and all other relevant breast cancer stakeholders worldwide to take action on three priority areas for women living with metastatic breast cancer (MBC)

The Metastatic Breast Cancer Advocacy Working Group, a cooperative of patient advocates from seven countries, released a consensus report urging other advocacy groups, health-care corporations and professionals, government, academia, community/religious organizations, and all other relevant breast cancer stakeholders worldwide to take action on three priority areas for women living with metastatic breast cancer (MBC):

• Improve access to tailored information, resources and support for women with MBC
• Heighten attention to the MBC community-create a unified voice and platform that speaks to their unique needs
• Increase understanding of and access to clinical trials.

“While there is no cure for MBC, women are living longer with metastatic disease than ever before, due in part to recent advances in treatment and supportive care,” said Dr. Marisa Weiss, Founder and President of Breastcancer.org, leading breast cancer oncologist and member of the MBC Advocacy Working Group. “It is now more critical than ever to address the complex emotional and medical needs of women dealing with metastatic disease through tailored resources and personalized support.”

Recent Videos
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
Related Content